DHG Pharmaceutical JSC (DHG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DHG Pharmaceutical JSC (DHG) has a cash flow conversion efficiency ratio of 0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₫447.50 Billion ≈ $17.00 Million USD) by net assets (₫4.18 Trillion ≈ $158.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DHG Pharmaceutical JSC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how DHG Pharmaceutical JSC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DHG liabilities breakdown for a breakdown of total debt and financial obligations.
DHG Pharmaceutical JSC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DHG Pharmaceutical JSC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock Limited Duration Income Trust
NYSE:BLW
|
0.038x |
|
Anhui Shiny Electronic Technology Company Limited
SHE:300956
|
N/A |
|
BlackRock Core Bond Closed Fund
NYSE:BHK
|
0.030x |
|
Compagnie du Bois Sauvage SA
BR:COMB
|
0.093x |
|
Issta Lines Ltd
TA:ISTA
|
0.034x |
|
Hubei Fuxing Science and Technology Co Ltd
SHE:000926
|
-0.049x |
|
ValueHD Corp. A
SHE:301318
|
0.002x |
|
Picpay Holdings Netherlands N.V. Class A Common Shares
NASDAQ:PICS
|
0.453x |
Annual Cash Flow Conversion Efficiency for DHG Pharmaceutical JSC (2019–2025)
The table below shows the annual cash flow conversion efficiency of DHG Pharmaceutical JSC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see DHG market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₫4.18 Trillion ≈ $158.91 Million |
₫1.22 Trillion ≈ $46.51 Million |
0.293x | -9.05% |
| 2024-12-31 | ₫4.09 Trillion ≈ $155.58 Million |
₫1.32 Trillion ≈ $50.06 Million |
0.322x | +457.94% |
| 2023-12-31 | ₫4.85 Trillion ≈ $184.38 Million |
₫279.88 Billion ≈ $10.63 Million |
0.058x | -72.54% |
| 2022-12-31 | ₫4.29 Trillion ≈ $163.05 Million |
₫901.28 Billion ≈ $34.24 Million |
0.210x | +76.07% |
| 2021-12-31 | ₫3.79 Trillion ≈ $144.12 Million |
₫452.44 Billion ≈ $17.19 Million |
0.119x | -48.49% |
| 2020-12-31 | ₫3.57 Trillion ≈ $135.56 Million |
₫826.17 Billion ≈ $31.39 Million |
0.232x | -6.70% |
| 2019-12-31 | ₫3.38 Trillion ≈ $128.33 Million |
₫838.24 Billion ≈ $31.85 Million |
0.248x | -- |
About DHG Pharmaceutical JSC
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, and dermatology and beauty care products. It also manufactures a… Read more